MetaCure

MetaCure is dedicated to enhancing the lives of individuals managing type 2 diabetes. As a member of the esteemed Hobart Group, MetaCure specializes in the development, production, and distribution of the DIAMOND therapy, an innovative alternative to insulin. This therapy is administered through a unique implantable device system designed to address the daily challenges faced by patients.

The DIAMOND therapy is specifically tailored for obese patients with type 2 diabetes who have not responded adequately to oral medications. Clinical trials involving over 300 patients have affirmed the safety and effectiveness of the DIAMOND therapy, demonstrating comparable efficacy to insulin treatment while mitigating many associated side effects and eliminating the need for frequent blood tests and injections. MetaCure's DIAMOND therapy is delivered via a pacemaker-like device implanted in the abdomen, which emits gentle electrical signals to the stomach during meals, thereby improving glycemic control and promoting weight loss.

MetaCure's system has been awarded the CE mark and is approved for sale in Europe, Australia, and various other international markets. The primary address for MetaCure is located at 101 Front Street, Hamilton, BM, with an additional office in Germany at MetaCure Germany GmbH, Breitwiesenstraße 19, Stuttgart, 70565, DE. We invite the management team at MetaCure to enrich our platform with a customized and exclusive company showcase and product listings.